Medline and Biomerica sign agreement for distribution of Biomerica’s colorectal screening test
Biomerica (Nasdaq:BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect colorectal disease screening test designed to help identify an early warning sign of colorectal cancer. As quoted in the press release: The EZ Detect colorectal screening test is the simplest at home test to … Continued
Biomerica (Nasdaq:BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect colorectal disease screening test designed to help identify an early warning sign of colorectal cancer.
As quoted in the press release:
The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. The test does not require handling of stool or dietary restrictions. The EZ Detect pad is tossed into the toilet after a bowel movement. A change in the pad’s color to blue/green, which would appear within two minutes, indicates the presence of blood in the stool. The pad is then simply flushed.
With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies. Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).
Colorectal cancer is the third leading cause of cancer-related deaths in men and women in the United States. It’s expected to cause about 50,630 deaths during 20181. There were an estimated 1,332,085 people living with colorectal cancer in the United States in 20152.
